Alpelisib has demonstrated significant efficacy in the treatment of advanced breast cancer with a PIK3CA mutation. However, targeted inhibition of the PI3K pathway can cause multisystem adverse reactions affecting the metabolic, skin, gastrointestinal, and respiratory systems, which requires careful monitoring throughout treatment and timely dose adjustment.
I. Metabolic disorders and the risk of hyperglycemia
1. The mechanism of hyperglycemia development
Inhibition of PI3Ka directly affects insulin signaling, which leads to an increase in blood glucose levels. This is the most pronounced target effect of this drug, which significantly increases the risk in patients with diabetes mellitus and high-risk groups.
2. Clinical manifestations of hyperglycemia
Patients may experience polydipsia, polyuria, and increased appetite during weight loss. In severe cases, ketoacidosis or hyperosmolar non-ketotic syndrome may develop, which requires vigilance.
3. Preventive intervention strategies
Before starting treatment, fasting glucose and HbA1c levels should be measured, as well as glycemic control optimized. It is believed that the prophylactic use of metformin reduces the frequency and severity of hyperglycemia, but it should be borne in mind that metformin may increase adverse reactions from the gastrointestinal tract, such as nausea, vomiting and diarrhea.
4. Principles of monitoring and management
At the initial stage of treatment, fasting glucose levels should be monitored weekly, then every 4 weeks after stabilization. The HbA1c level should be checked every 3 months. If hyperglycemia occurs, antihyperglycemic therapy should be initiated or intensified. Based on the glucose level, decide whether to interrupt, reduce, or permanently discontinue treatment.
ii. Skin and allergic reactions
1. Common rash symptoms
Rash is the most common skin adverse reaction to this medication, often manifesting itself as a spotty papular rash, erythema, or generalized rash that usually occurs at the beginning of treatment.
2. Severe skin side effects
In rare cases, patients may develop life-threatening conditions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or a drug reaction with eosinophilia and systemic symptoms. If you experience prodromal fever, mucosal lesions, blisters, or skin detachment, stop treatment immediately and consult a doctor.
3. Strategies for dealing with rash actions
Mild rash can be treated with topical corticosteroids and oral antihistamines. If the rash persists or worsens, you should consider reducing the dose or discontinuing the drug after consulting with a dermatologist.
4. Severe allergic reactions
Anaphylactic shock, angioedema, and other immediate hypersensitivity reactions may develop, manifested by shortness of breath, redness of the face, fever, or tachycardia. If this happens, stop treatment permanently and provide emergency care.
iii. Gastrointestinal and respiratory toxicity
1. Diarrhea and colitis
Diarrhea is common, and some patients experience severe diarrhea, leading to dehydration and kidney damage. Antidiarrheal medications such as loperamide may be used, as well as enhanced fluid replenishment in the mouth. If abdominal pain, hematocheesia, or mucous stools occur, the possibility of developing colitis should be considered. In severe cases, enteric or systemic corticosteroid therapy may be required.
2. Damage to the oral mucosa
Stomatitis, inflammation of the mucous membranes and dysgeusia are common and can affect food intake. It is recommended to observe oral hygiene and use mild mouthwash. In severe cases, dose adjustment may be required.
3. Pneumonitis and interstitial lung diseases
If you experience new or worsening symptoms of shortness of breath, cough, hypoxia, or with visualizations indicating interstitial infiltration, discontinue treatment immediately and assess for the presence of pneumonitis. If the pneumonitis is confirmed, discontinue treatment completely.
4. Other systemic adverse reactions
Some patients may experience increased fatigue, decreased appetite, weight loss, and baldness. Women of childbearing age should be aware of the risk of toxic effects on the embryo and fetus and should use effective contraceptives during treatment and within 1 week after taking the last dose.
